LH Stock Recent News
LH LATEST HEADLINES
Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.
Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Labcorp (LH) came out with quarterly earnings of $3.38 per share, beating the Zacks Consensus Estimate of $3.37 per share. This compares to earnings of $4.68 per share a year ago.
Laboratory Corporation of America topped Wall Street expectations for quarterly adjusted profit on Thursday, as strength in its routine diagnostics business more than offset weak COVID test sales.
Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.
Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting disease and potentially helping patients access treatment.
BURLINGTON, N.C. , Sept. 29, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the third quarter of 2023 before the market opens on Thursday, October 26, 2023.
Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.
Labcorp's (LH) Early Development Research Laboratories business continues to be constrained by NHP-related supply-chain issues.
A rise in organic revenues, acquisitions, net of divestitures and foreign currency translation drive LabCorp's (LH) Q2 revenues.